Levitee Labs - CEO, Pouya Farmand.
CEO, Pouya Farmand.
Source: Levitee Labs.
  • Levitee Labs (LVT) appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada
  • Dr. Mosli has over a decade of healthcare experience specializing in addiction, leading innovation in reorienting health systems, and increasing health equality
  • Dr. Mosli spent the last five years as a Medical Officer of Canada’s largest province-wide, fully-integrated health system that serves over four million patients
  • He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree in the field of Medical Sciences from King Abdulaziz University in Saudi Arabia
  • Levitee Labs Inc. (LVT) is down 2.20 per cent, trading at C$0.44 at 10:17 am ET

Levitee Labs Inc (LVT) appoints Mohammed H Mosli, MD, FRCPC, ISAM, as Chief People Officer (CPO) of Levitee Clinics™ and Levitee Pharmacies™.

In this role, Dr. Mosli will oversee managing the strategy and processes related to building and retaining an exceptional team of professionals and will optimize people-centred activities such as hiring, training, professional development, and performance management.

He will oversee 60 active employees in Alberta, to ensure these efforts support the continued growth of Levitee Clinics™ and Levitee Pharmacies™ across North America.

Dr. Mosli is a multilingual Public Health and Preventive Medicine physician specialized in Addictions Health, health services improvement, health promotion, environmental public health, and health policy.

Throughout his career, Dr. Mosli served or currently serves as a director, educator, or senior-level manager for an array of organizations, including those in provincial, institutional, and private segments. He is a valuable physician member of the Opioid Addictions Medicine team for Levitee Clinics™ and Levitee Pharmacies™ in Alberta.

“Dr. Mosli has spent his career working with multi-disciplinary teams to provide focused medical care to vulnerable populations, including opioid agonist therapy, alcohol addiction therapy, Hepatitis C treatment, and many more,” said Pouya Farmand, Chief Executive Officer at Levitee Labs™.

“He exudes leadership and has consistently demonstrated unparalleled skills to organize teams and manage individuals at major organizations to achieve goals with the utmost efficiency, qualities that will be invaluable to us as we continue to roll-up companies and expand our operations nationwide.”

“I have always been passionate about leading innovation in reorienting health systems, increasing health equality, and protecting the wellbeing of local, national, and global population with an evidence-based approach,” commented Dr. Mosli.

“My goals align perfectly with those of Levitee Labs™ and I look forward to being a leader during this phase of rapid growth for the company.”

Dr. Mosli earned his FRCPC (Fellow of the Royal College of Physicians of Canada) degree from the University of Calgary in Public Health and Preventive Medicine. He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree in the field of Medical Sciences from King Abdulaziz University in Saudi Arabia.

Levitee Labs™ is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labsaims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies into a medical home care model.

Levitee Labs Inc. (LVT) is down 2.20 per cent, trading at C$0.44 at 10:17 am ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.